Reliance Industries Limited (RELIANCE) — Announcement

· NSE Neutral
📢 Key Event
Karkinos Healthcare crosses one lakh HPV DNA tests milestone
🔮 What's Next
carrying this journey forward to one million tests next, and to one hundred million responsibly
💡 Investor Takeaway
This demonstrates Reliance's expansion into scalable healthcare services with potential for long-term value creation through digital health infrastructure.

Reliance Industries announced that its 100% subsidiary Karkinos Healthcare has completed HPV DNA screening for over one lakh women across India, marking a milestone in cervical cancer prevention. The company highlighted its digitally enabled care continuum that ensures follow-up for positive cases, addressing a key gap in public health programs. This achievement underscores Reliance's commitment to scalable, technology-driven healthcare solutions in underserved communities.

📄 View Original Announcement (PDF)

About Reliance Industries Limited (RELIANCE)

Oil Gas & Consumable Fuels · Petroleum Products · Listed on NSE

Market Cap: ₹18,08,488.47 Cr P/E: 21.7 ROE: 9.9% ROCE: 11.2%

View full RELIANCE stock details →

📡 Get AI alerts when RELIANCE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track RELIANCE — Free

📊 More RELIANCE filings

See all RELIANCE filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when RELIANCE files new disclosures

Track RELIANCE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track RELIANCE — Free

Free account · 2 AI queries/day